Pharma BD Deal Intelligence
Allergan's $95M bet on ForSight's bimatoprost ring never cleared Phase 2 noninferiority and was quietly shelved — a near-total write-off.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Allergan CEO Brent Saunders framed the acquisition as building on 'Allergan's rich history and deep commitment to eye-care innovation,' with the technology…
Allergan to acquire ForSight VISION5 for $95 million, gaining a preservative-free periocular ring delivering bimatoprost over six months to reduce intraocular…
Zacks framed the acquisition as a strategic boost to Allergan's glaucoma pipeline alongside the company's broader eye-care franchise; deal closed within…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Allergan acquired ForSight VISION5, a clinical-stage eye care biotech, for ~$95M all-cash. Lead asset was a sustained-release bimatoprost periocular ring for glaucoma/ocular hypertension. Strengthened Allergan's eye care pipeline alongside Restasis franchise.
Allergan's $95M bet on ForSight's bimatoprost ring never cleared Phase 2 noninferiority and was quietly shelved — a near-total write-off.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Allergan plc / ForSight VISION5, Inc. (this deal) | 2016 | $95M | 17 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Allergan plc / SkinMedica, Inc. | 2012 | $375M | 55 |
| Allergan plc / Inamed Corporation | 2005 | $3.2B | 50 |
| Allergan plc / Oculeve, Inc. | 2015 | $250M | 33 |
| Allergan plc / Zeltiq Aesthetics, Inc. | 2017 | $2.5B | 32 |
| Allergan plc / Kythera Biopharmaceuticals, Inc. | 2015 | $2.1B | 23 |
← Browse all deals · How we score deals
More: 2016 deals · Allergan plc deals · Cardiovascular deals